Nintedanib in Post-COVID Interstitial Lung Disease: a double-blind, randomized, placebo-controlled Clinical Trial
{{output}}
Rationale: The optimal treatment of interstitial lung disease resulting from COVID-19 is unknown. Objectives: We sought to investigate the effe... ...
